Stockreport

VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints  

VBI Vaccines, Inc. - Ordinary Shares  (VBIV) 
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: vbivaccines.com/investors
PDF Lot-to-lot manufacturing consistency of Sci-B-Vac®, the primary endpoint, was demonstratedSci-B-Vac® achieved seroprotection rates of 99.3% and 90.4% after three and two [Read more]